World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
53504
World Ranking
11955
National Ranking
1130

Juan W. Valle publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Juan W. Valle sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 712 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Juan W. Valle D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Juan W. Valle sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Juan W. Valle is affiliated with the University of Manchester in the United Kingdom and has a substantial body of work in the field of medicine, with a focus on oncology. Their research contributions span multiple subfields including oncology, surgery, pulmonary and respiratory medicine, epidemiology, and cancer research.

Their main research topics cover several areas within cancer studies, such as:

  • Cholangiocarcinoma and gallbladder cancer studies
  • Pancreatic and hepatic oncology research
  • Neuroendocrine tumor research advances
  • Gallbladder and bile duct disorders
  • Lung cancer research studies
  • Neuroblastoma research and treatments
  • Cancer genomics and diagnostics

Juan W. Valle has contributed to several recent papers in prominent journals, including:

  • Biliary tract cancer, 2021, The Lancet
  • Pancreatic cancer, 2020, The Lancet
  • Cholangiocarcinoma 2020: the next horizon in mechanisms and management, 2020, Nature Reviews Gastroenterology & Hepatology
  • Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study, 2020, The Lancet Oncology
  • Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer, 2022, NEJM Evidence

The venues where Juan W. Valle frequently publishes include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancers
  • Journal of Hepatology
  • British Journal of Cancer

Co-authorship is an important aspect of Juan W. Valle's research activity. They have frequently collaborated with:

  • Ángela Lamarca
  • Mairéad G. McNamara
  • Richard Hubner
  • John Bridgewater
  • Robin Kate Kelley

The overall publication record reflects a focus on clinical and experimental oncology, with a particular emphasis on cancers of the biliary tract, pancreas, and related organ systems. The combination of research topics, collaborative network, and publication venues situates Juan W. Valle within an active scientific community dedicated to advancing understanding and management of complex cancer types.

Best Publications

  • Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

    Juan Ignacio Valle;Harpreet Singh Wasan;Daniel H Palmer;David Cunningham

  • Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

    Eric Raymond;Laetitia Dahan;Jean Luc Raoul;Yung Jue Bang

  • Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

    John P. Neoptolemos;John P. Neoptolemos;Daniel H. Palmer;Daniel H. Palmer;Paula Ghaneh;Eftychia E. Psarelli

  • Cholangiocarcinoma 2020: the next horizon in mechanisms and management

    Jesus M. Banales;Jesus M. Banales;Jesus M. Banales;Jose J. G. Marin;Jose J. G. Marin;Angela Lamarca;Angela Lamarca;Pedro M. Rodrigues

  • Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

    John P. Neoptolemos;Deborah D. Stocken;Claudio Bassi;Paula Ghaneh

  • Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    James C. Yao;Nicola Fazio;Simron Singh;Roberto Buzzoni

  • Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.

    John N Primrose;Richard P Fox;Daniel H Palmer;Hassan Z Malik

  • Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

    David Cunningham;Ian Chau;Deborah D. Stocken;Juan W. Valle

  • Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)

    John K Ramage;A Ahmed;J Ardill;N Bax

  • Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    Ghassan K. Abou-Alfa;Ghassan K. Abou-Alfa;Teresa Macarulla;Milind M. Javle;Robin K. Kelley

  • Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.

    Angela Lamarca;Daniel H Palmer;Harpreet Singh Wasan;Paul J Ross

  • Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer

    P J Ross;Marianne Nicolson;David Cunningham;Juan W Valle

  • Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    J W Valle;Ivan Borbath;S A Khan;F Huguet

  • Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.

    John P. Neoptolemos;Malcolm J. Moore;Trevor F. Cox;Juan W. Valle

  • Biliary tract cancer

    Juan W. Valle;Juan W. Valle;R. Katie Kelley;Bruno Nervi;Do Youn Oh

  • New Horizons for Precision Medicine in Biliary Tract Cancers

    Juan W. Valle;Angela Lamarca;Lipika Goyal;Jorge Barriuso

  • Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial

    J Primrose;S Falk;M Finch-Jones;Juan W Valle

  • Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study

    Juan W. Valle;Daniel Palmer;Richard Jackson;Trevor Cox

  • Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials

    Juan W Valle;J Furuse;M Jitlal;S Beare

  • Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial

    JP Neoptolemos;MJ Moore;TF Cox;JW Valle

Frequent Co-Authors

David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust
John P. Neoptolemos
John P. Neoptolemos Heidelberg University
Matthew H. Kulke
Matthew H. Kulke Boston Medical Center
Tim Meyer
Tim Meyer University College London
Ghassan K. Abou-Alfa
Ghassan K. Abou-Alfa Memorial Sloan Kettering Cancer Center
Eric Raymond
Eric Raymond St. Joseph Hospital
Arndt Vogel
Arndt Vogel Hannover Medical School
Caroline Dive
Caroline Dive University of Manchester
Bengt Glimelius
Bengt Glimelius Uppsala University
Jean-Luc Raoul
Jean-Luc Raoul Institut de Cancérologie de l'Ouest (ICO)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The medical field offers diverse online degree programs that can open doors to new career opportunities or expand current skills. If you are a registered nurse interested in becoming a nurse practitioner, there are rn to np bridge programs designed to streamline the process and minimize time spent in traditional classrooms.

For those drawn to preventative health and wellness, a bachelor's in nutrition online can provide foundational knowledge in dietetics and open pathways in both clinical and community health careers.

Aspiring healthcare administrators may benefit from enrolling in a cahme accredited online mha program. This can help build expertise in leadership, healthcare policy, and strategic management—skills crucial for advancing in healthcare management roles.

Additionally, working nurses seeking to further their education might consider an online rn to bsn no clinicals program, which can offer flexibility and eliminate the need for added on-site clinicals.

Best Scientists Citing Juan W. Valle

Trending Scientists

Recently Published Articles